_{This free version is ad-supported.}

Everyone’s hunting for the next Unicorn.

The type of “category disruptor” that grows fast and turns early believers into big winners.

59,000+ investors think that Mode Mobile could be one of those rare finds.

Americans spend 4 ½ hours on their phones daily, and Mode Mobile is monetizing that screentime. With $1B+ earned by over 490M customers and 32,481% revenue growth, Mode’s EarnPhone is turning smartphones into income generating assets.

Their previous raises sold out, and the company is now offering pre-IPO shares at $0.52/share with up to 20% bonus, exclusive to early investors.

Being early is everything, and this window is still open.

>> Review the offer before it closes

^{*Please read the offering circular and related risks at invest.modemobile.com.}

^{Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.}

^{The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.}

Don’t want to see ads anymore? Click here for an ad-free experience

_{This free version is ad-supported.}

It just surpassed a $1B valuation, joining private US companies like SpaceX and OpenAI. Unlike them, you can invest in EnergyX today. General Motors already has. Why? EnergyX’s tech can recover up to 3X more lithium than traditional methods. Now, they hold rights to ~13M tons of lithium across North and South America. Invest in EnergyX at $13/share by 7/16.

Invest in EnergyX

^{Energy Exploration Technologies, Inc. (“EnergyX”) has engaged Beehiiv to publish this communication in connection with EnergyX’s ongoing Regulation A offering. Beehiiv has been paid in cash and may receive additional compensation. Beehiiv and/or its affiliates do not currently hold securities of EnergyX.}

^{This compensation and any current or future ownership interest could create a conflict of interest. Please consider this disclosure alongside EnergyX’s offering materials. EnergyX’s Regulation A offering has been qualified by the SEC. Offers and sales may be made only by means of the qualified offering circular. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at invest.energyx.com/.}

^{Comparisons to other companies are for informational purposes only and should not imply similar results. Past performance is not indicative of future results. Market shortfall are forward‑looking estimates and are subject to substantial uncertainty.}

Don’t want to see ads anymore? Click here for an ad-free experience

You probably have a bottle of melatonin in your house.

Most of us do. It feels safe. It sits right next to the vitamin C at the pharmacy, usually flavored like mixed berries.

But melatonin isn't a vitamin. It’s a hormone.

And we are taking massive, unnatural doses of it.

A standard 10-milligram gummy gives you about 30 times what your brain naturally produces.

The strange part? Clinical data shows it barely even helps you sleep. On average, it only adds about eight minutes to your night.

But it does do something else. Something the supplement companies don't mention.

It messes with your blood sugar.

When you have high levels of melatonin in your blood and you eat a late-night snack, the hormone acts as a brake on your insulin. It creates a biological collision. And because of a common genetic variant, half the population is especially vulnerable to this trap.

We ignored the wellness marketing and went straight to the clinical trials.

Here is the unvarnished truth about the world's favorite "natural" sleep aid.

The 30x Overdose: Why the Math is Wrong
You take a vitamin, your body flushes the excess. Hormones don't work that way. We explain the massive gap between what your pineal gland actually makes (a tiny trickle) and the 10mg gummies sold at the store. [Section 1: The Proactive Anchor]

The Blindspot: What's Really in the Bottle
In Europe, it’s a prescription drug. Here, it’s a largely unregulated supplement. We look at the Harvard data showing 88% of melatonin products are mislabeled. Plus, we explain why the receptors that matter most aren't just in your brain—they are in your pancreas. [Section 2: The Blindspot]

The Biological Collision: When Sleep Meets Food
This is the danger zone. Taking melatonin while eating a late snack signals your pancreas to stop releasing insulin right when you need it most. We break down the studies and the specific gene—carried by half of us—that amplifies this blood-sugar spike. [Section 3: The Real Paradox]

The 8-Minute Myth: Does It Actually Work?
We clear up the rumors about weight gain and vivid dreams. But the biggest reality check is the efficacy. Pooled data shows melatonin only cuts the time it takes to fall asleep by seven minutes. We look at the actual data behind the habit. [Section 4: Signal and Noise]

The Real Off-Switch: Fixing Your Clock
You don't need another pill to sleep well. You need light. We lay out the biological levers that actually control your circadian rhythm, starting with morning sun and shifting when you eat your meals. [Section 5: The Science of Reversal]

The Step-Down Protocol: Finding Your Floor
The good news? Melatonin isn't physically addictive. There is no withdrawal. We give you a simple, evidence-based roadmap to step down to a harmless micro-dose and let your natural biology take over. [Section 6: The Protocol]

This isn't about throwing away your supplements. It's about knowing exactly how they work.

Get the full story.

Some taxpayers may be owed refunds from COVID-era penalties and interest.

But the July Regulatory Docket flags the dangerous part:

The general protective-claim deadline is July 10, 2026.

A household that paid the maximum failure-to-file penalty on a $50,000 balance paid $12,500 before interest.

Relief will not arrive automatically.

You have to know to ask.

That is the point of The Regulatory Docket.

Every month, it turns dense tax, estate, Medicare, retirement, and state-rule changes into plain-English action intelligence for affluent households.

Normally: $189/month or $1,890/year.
Summer Rate: $50/month or $500/year — 74% off.

One missed deadline can cost more than years of this report.

Subscribe before the Summer Rate closes.

Information is free. Intelligence is scarce.

You are one of 550,000 readers receiving this briefing. That is a crowd.

To join the 1,800 investors who receive our redacted contract briefings and wealth defense protocols, you need to step behind the velvet rope.

Join the Inner Circle.